JPWO2020074894A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020074894A5 JPWO2020074894A5 JP2021517866A JP2021517866A JPWO2020074894A5 JP WO2020074894 A5 JPWO2020074894 A5 JP WO2020074894A5 JP 2021517866 A JP2021517866 A JP 2021517866A JP 2021517866 A JP2021517866 A JP 2021517866A JP WO2020074894 A5 JPWO2020074894 A5 JP WO2020074894A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- use according
- weight
- rpl554
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000002245 particle Substances 0.000 claims 9
- CSOBIBXVIYAXFM-BYNJWEBRSA-N ensifentrine Chemical compound c-12cc(OC)c(OC)cc2CCn(c(n2CCNC(N)=O)=O)c-1c\c2=N/c1c(C)cc(C)cc1C CSOBIBXVIYAXFM-BYNJWEBRSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- PVKCAQKXTLCSBC-UHFFFAOYSA-N 1h-isoquinolin-4-one Chemical compound C1=CC=C2C(=O)C=NCC2=C1 PVKCAQKXTLCSBC-UHFFFAOYSA-N 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024091837A JP2024113096A (ja) | 2018-10-09 | 2024-06-05 | Ｈｆａ－１３４ａ中のｒｐｌ５５４を含む吸入による投与用医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816447.5 | 2018-10-09 | ||
| GB1816447.5A GB2578093B (en) | 2018-10-09 | 2018-10-09 | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| PCT/GB2019/052863 WO2020074894A1 (en) | 2018-10-09 | 2019-10-09 | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091837A Division JP2024113096A (ja) | 2018-10-09 | 2024-06-05 | Ｈｆａ－１３４ａ中のｒｐｌ５５４を含む吸入による投与用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513566A JP2022513566A (ja) | 2022-02-09 |
| JPWO2020074894A5 true JPWO2020074894A5 (enExample) | 2022-10-11 |
| JP7578587B2 JP7578587B2 (ja) | 2024-11-06 |
Family
ID=64394831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517866A Active JP7578587B2 (ja) | 2018-10-09 | 2019-10-09 | Ｈｆａ－１３４ａ中のｒｐｌ５５４を含む吸入による投与用医薬組成物 |
| JP2024091837A Pending JP2024113096A (ja) | 2018-10-09 | 2024-06-05 | Ｈｆａ－１３４ａ中のｒｐｌ５５４を含む吸入による投与用医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091837A Pending JP2024113096A (ja) | 2018-10-09 | 2024-06-05 | Ｈｆａ－１３４ａ中のｒｐｌ５５４を含む吸入による投与用医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20210379053A1 (enExample) |
| EP (2) | EP3960157A1 (enExample) |
| JP (2) | JP7578587B2 (enExample) |
| KR (1) | KR20210073532A (enExample) |
| CN (1) | CN112912064B (enExample) |
| AU (1) | AU2019358585B2 (enExample) |
| BR (1) | BR112021006712A2 (enExample) |
| CA (1) | CA3113167A1 (enExample) |
| CY (1) | CY1124943T1 (enExample) |
| DK (1) | DK3820446T3 (enExample) |
| ES (1) | ES2899744T3 (enExample) |
| GB (1) | GB2578093B (enExample) |
| HR (1) | HRP20220053T1 (enExample) |
| HU (1) | HUE057780T2 (enExample) |
| IL (1) | IL282032A (enExample) |
| LT (1) | LT3820446T (enExample) |
| MX (2) | MX2021003599A (enExample) |
| MY (1) | MY207302A (enExample) |
| PH (1) | PH12021550767A1 (enExample) |
| PL (1) | PL3820446T3 (enExample) |
| PT (1) | PT3820446T (enExample) |
| RS (1) | RS62775B1 (enExample) |
| SG (1) | SG11202102567UA (enExample) |
| SI (1) | SI3820446T1 (enExample) |
| SM (1) | SMT202200044T1 (enExample) |
| WO (1) | WO2020074894A1 (enExample) |
| ZA (1) | ZA202102039B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB2594480A (en) * | 2020-04-28 | 2021-11-03 | Verona Pharma Plc | New treatment |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| JP2025534762A (ja) * | 2022-10-28 | 2025-10-17 | 江蘇恒瑞医薬股▲ふん▼有限公司 | イソキノリノン系化合物を含む医薬組成物及びその調製方法 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| US12194045B1 (en) | 2023-06-26 | 2025-01-14 | Verona Pharma Plc | Particulate composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000058308A1 (en) | 1999-03-31 | 2000-10-05 | Vernalis Limited | DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE |
| DK2603509T3 (da) * | 2010-08-09 | 2014-09-08 | Verona Pharma Plc | KRYSTALLINSK FORM AF PYRIMIDIO [6,1- a] ISOQUINOLIN-4-ON-FORBINDELSE |
| KR20150041608A (ko) * | 2012-02-28 | 2015-04-16 | 아이슈티카 홀딩스 인코포레이티드. | 흡입용 약제학적 조성물 |
| PT2968312T (pt) | 2013-03-15 | 2018-04-19 | Verona Pharma Plc | Combinação de fármacos |
| PL3231444T3 (pl) * | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| HUE055527T2 (hu) * | 2014-09-15 | 2021-12-28 | Verona Pharma Plc | RPL554-t tartalmazó folyékony inhalációs készítmény |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2018
- 2018-10-09 GB GB1816447.5A patent/GB2578093B/en active Active
-
2019
- 2019-10-09 PT PT197907181T patent/PT3820446T/pt unknown
- 2019-10-09 CN CN201980065895.8A patent/CN112912064B/zh active Active
- 2019-10-09 EP EP21198029.7A patent/EP3960157A1/en active Pending
- 2019-10-09 SM SM20220044T patent/SMT202200044T1/it unknown
- 2019-10-09 LT LTEPPCT/GB2019/052863T patent/LT3820446T/lt unknown
- 2019-10-09 DK DK19790718.1T patent/DK3820446T3/da active
- 2019-10-09 HU HUE19790718A patent/HUE057780T2/hu unknown
- 2019-10-09 MY MYPI2021001479A patent/MY207302A/en unknown
- 2019-10-09 SI SI201930145T patent/SI3820446T1/sl unknown
- 2019-10-09 PL PL19790718T patent/PL3820446T3/pl unknown
- 2019-10-09 ES ES19790718T patent/ES2899744T3/es active Active
- 2019-10-09 RS RS20211599A patent/RS62775B1/sr unknown
- 2019-10-09 BR BR112021006712-4A patent/BR112021006712A2/pt unknown
- 2019-10-09 US US17/280,452 patent/US20210379053A1/en not_active Abandoned
- 2019-10-09 HR HRP20220053TT patent/HRP20220053T1/hr unknown
- 2019-10-09 AU AU2019358585A patent/AU2019358585B2/en active Active
- 2019-10-09 JP JP2021517866A patent/JP7578587B2/ja active Active
- 2019-10-09 CA CA3113167A patent/CA3113167A1/en active Pending
- 2019-10-09 KR KR1020217010706A patent/KR20210073532A/ko not_active Ceased
- 2019-10-09 SG SG11202102567UA patent/SG11202102567UA/en unknown
- 2019-10-09 WO PCT/GB2019/052863 patent/WO2020074894A1/en not_active Ceased
- 2019-10-09 MX MX2021003599A patent/MX2021003599A/es unknown
- 2019-10-09 EP EP19790718.1A patent/EP3820446B1/en active Active
-
2021
- 2021-03-25 ZA ZA2021/02039A patent/ZA202102039B/en unknown
- 2021-03-26 MX MX2024001499A patent/MX2024001499A/es unknown
- 2021-04-04 IL IL282032A patent/IL282032A/en unknown
- 2021-04-06 PH PH12021550767A patent/PH12021550767A1/en unknown
-
2022
- 2022-02-02 CY CY20221100086T patent/CY1124943T1/el unknown
-
2024
- 2024-03-26 US US18/616,878 patent/US20250049781A1/en active Pending
- 2024-06-05 JP JP2024091837A patent/JP2024113096A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211035T1 (hr) | Tekuća formulacija za inhalaciju koja sadrži rpl554 | |
| JP2024113096A5 (enExample) | ||
| ES2266322T3 (es) | Nuevo uso de budesonida y formoterol. | |
| JP2017528479A5 (enExample) | ||
| KR20120015295A (ko) | 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형 | |
| JP2019534270A5 (enExample) | ||
| CN102946868A (zh) | 包含抗毒蕈碱药的干粉制剂 | |
| AU2005316687B2 (en) | Compositions and methods for pulmonary conditions | |
| JP2009515941A (ja) | 医薬組成物 | |
| JPWO2020074894A5 (enExample) | ||
| HRP20240288T1 (hr) | Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat | |
| HUP0303755A2 (hu) | Szalmeterol és flutikaszon-propionát kombináció alkalmazása és ezt tartalmazó gyógyszerkészítmény | |
| JPWO2021028679A5 (enExample) | ||
| CN105307639B (zh) | 包含与载体颗粒结合的活性剂纳米颗粒的干药物组合物 | |
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| JP2008502699A5 (enExample) | ||
| KR102637303B1 (ko) | 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법 | |
| KR102637298B1 (ko) | 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법 | |
| RU2021109697A (ru) | Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции | |
| JPWO2019204583A5 (enExample) | ||
| RU2022103508A (ru) | Фармацевтическая композиция, содержащая энсифентрин | |
| NZ767296B2 (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| AU2020361747A1 (en) | An inhalable dry powder composition for pulmonary diseases | |
| Kearns et al. | 88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF) | |
| KR20090130360A (ko) | 섬유모세포 성장인자 2를 유효성분으로 함유하는 천식 및 만성폐쇄성 폐질환 치료 또는 예방을 위한 흡입용 약제학적 조성물 |